hard to judge - but assuming same cashflow as December quarter...

hard to judge - but assuming same cashflow as December quarter (and stripping out R&D grant received, interest paid - as loan was repaid, and other costs that dont seem to recur) - i get negative $2.088m deficiency. Cash on Hand $3.325m - i think December qtr included the CR proceeds.

so assuming that there are other cost savings (as R&D heavy that qtr) then i would assume June qtr coming close to cash short so something will need to give - or another CR on its way.

really depends on cost savings they look/have looked at implementing - if cut R&D or staffing levels than that may prolong development of product and just kick the can down the road as far as cashflow goes. Maybe that is the MO here in order to put space between recent CR and any future required CR?.